Stockscreener 앱 받기
2.17
1.81%
-0.04
전일 마감가:
$2.21
열려 있는:
$2.22
하루 거래량:
208.19K
Relative Volume:
0.12
시가총액:
$172.80M
수익:
-
순이익/손실:
$-40.33M
주가수익비율:
-1.2123
EPS:
-1.79
순현금흐름:
$-39.53M
1주 성능:
+1.88%
1개월 성능:
+33.95%
6개월 성능:
-33.23%
1년 성능:
-53.53%
1일 변동 폭
$2.14
$2.2699
1주일 범위
$2.06
$2.33
52주 변동 폭
$1.35
$4.965
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
명칭
Eledon Pharmaceuticals Inc
전화
949-238-8090
주소
19800 MACARTHUR BLVD., IRVINE
ELDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.17 | 175.98M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.30 | 118.13B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.14 | 79.79B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
846.94 | 52.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.19 | 46.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.75 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Guggenheim | Buy |
| 2022-05-13 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 개시 | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Up 3.6% – Should You Buy? - Defense World
Eledon Pharmaceuticals: Sustained Tegoprubart Efficacy, Differentiated Safety, and Upcoming Transplant Catalysts Support Buy Rating - TipRanks
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - Sahm
Eledon reports positive 24-month kidney transplant data for tegoprubart By Investing.com - Investing.com India
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Craig-Hallum Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating - 富途资讯
Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter Symposium - marketscreener.com
Eledon Pharmaceuticals (ELDN) to Reveal Promising Kidney Transpl - GuruFocus
Eledon reports positive 24-month kidney transplant data for tegoprubart - Investing.com
2-year transplant data: Eledon's tegoprubart shows no rejection in 8 patients - Stock Titan
Surprises Report: Is SDHC stock a value trapEarnings Overview Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Loss Report: Is Eledon Pharmaceuticals Inc stock a good dividend stock2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Growth Value: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts - Defense World
Buy Signal: Will Eledon Pharmaceuticals Inc stock deliver better than expected guidanceJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - Bộ Nội Vụ
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Eledon Pharmaceuticals Shares Sink After Announcing $50 Million Public Offering - MSN
Profit Review: Can Eledon Pharmaceuticals Inc. stock sustain market leadershipQuarterly Portfolio Report & Stepwise Swing Trade Plans - ulpravda.ru
Can Eledon Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - Улправда
How Eledon Pharmaceuticals Inc. (2TK) stock trades after earningsQuarterly Earnings Report & Community Verified Trade Signals - ulpravda.ru
Eledon’s tegoprubart shows promise in kidney transplantation trials By Investing.com - Investing.com South Africa
Eledon’s tegoprubart shows promise in kidney transplantation trials - Investing.com
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - The Manila Times
Can Eledon Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Update & Verified Entry Point Signals - Улправда
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3%Time to Buy? - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3% – Time to Buy? - Defense World
Is Eledon Pharmaceuticals Inc. (2TK) stock a defensive play amid uncertaintyCandlestick Pattern Analysis & Free Expert Stock Watchlists - ulpravda.ru
Cash per share of Eledon Pharmaceuticals, Inc. – MUN:2TK - TradingView — Track All Markets
Midday Stock Roundup: Lantronix Stock up 4.8% Today - Orange County Business Journal
Eledon Pharmaceuticals Restructures Stake via Pre-Funded Warrant - TipRanks
Midday Stock Roundup: Rivian Down on Production Totals - Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Eledon Pharmaceuticals (STU:2TK) EV-to-OCF : -0.29 (As of Dec. 31, 2025) - GuruFocus
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - Morningstar
Is Eledon Pharmaceuticals Inc. (2TK) stock a buy during volatile marketsProtective Put Strategies & Small Capital Growth Tips - bollywoodhelpline.com
Midday Stock Roundup: Shimmick Corp. climbs 14% - Orange County Business Journal
Sector Rotation Brings Aditya Birla Sun Life Amc Ltd Into FocusSmall Cap Stock Opportunities & Free ETF and Mutual Fund Comparisons - earlytimes.in
Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today? - MSN
Can Eledon Pharmaceuticals Inc. stock double in next 5 yearsStochastic Oscillator Alerts & Free High Yield Growth Strategies - Bollywood Helpline
Eledon Pharmaceuticals Inc (ELDN) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Analysts Set Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Target Price at $9.67 - Defense World
Eledon Pharmaceuticals Inc (ELDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
4.26%
자본화:
|
볼륨(24시간):